Back to Search
Start Over
Two engineered site-specific antibody-drug conjugates, HLmD4 and HLvM4, have potent therapeutic activity in two DLL4-positive tumour xenograft models
- Source :
- Am J Cancer Res
- Publication Year :
- 2022
- Publisher :
- e-Century Publishing Corporation, 2022.
-
Abstract
- The humanized Delta-like 4 (DLL4) monoclonal antibody H3L2 with a quite high affinity for hrDLL4 inhibits the DLL4-mediated human umbilical vein endothelial cell (HUVEC) phenotype, inducing dysfunctional angiogenesis and tumour cell apoptosis, which effectively arrests breast cancer cell growth
- Subjects :
- Erratum
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Am J Cancer Res
- Accession number :
- edsair.pmid..........21cdb2c8d7475d80a0e4638d400b4328